A Case of Sepsis Caused by Cellulitis in a Patient with Rheumatoid Arthritis after Tocilizumab Treatment

Tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor, is therapeutically effective in patients diagnosed with rheumatoid arthritis (RA) compared with placebo. However patients treated with tocilizumab are at increased risk of several adverse effects including anaphylaxis a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of rheumatic diseases 2016, 23(1), , pp.55-60
Main Authors: Yoo, Min Seok, Park, Ji Sang, Park, Yoon Suk, Kim, Hye Won, Hur, Jin-Wuk
Format: Article
Language:English
Subjects:
내과학
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor, is therapeutically effective in patients diagnosed with rheumatoid arthritis (RA) compared with placebo. However patients treated with tocilizumab are at increased risk of several adverse effects including anaphylaxis and serious infections that may lead to hospitalization or death. Therefore, the risks and benefits of treatment with tocilizumab should be considered carefully and close monitoring of patients for development of signs and symptoms of side effects is required during and after treatment. Here, we report on a rare case of anaphylaxis and severe sepsis caused by cellulitis in a patient with RA after tocilizumab treatment. (J Rheum Dis 2016;23:55-60) KCI Citation Count: 0
ISSN:2093-940X
2233-4718
DOI:10.4078/jrd.2016.23.1.55